Please wait
0001815442424B5EX-FILING FEES 0001815442 2025-06-27 2025-06-27 0001815442 1 2025-06-27 2025-06-27 0001815442 2 2025-06-27 2025-06-27 iso4217:USD xbrli:pure xbrli:shares
Exhibit 107
Calculation of Filing Fee Tables
S-3
(Form Type)
Kymera Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
 
                         
     Security
Type
 
Security
Class
Title
  Fee 
Calculation 
or Carry 
Forward 
Rule 
  Amount
Registered
  Proposed
Maximum
Offering
Price Per
Unit
 
Maximum
Aggregate
Offering
Price
  Fee Rate   Amount of
Registration
Fee
(1)
  Carry 
Forward 
Form 
Type 
  Carry 
Forward 
File 
Number 
  Carry 
Forward 
Initial 
effective 
date 
  Filing Fee
Previously
Paid In
Connection
with
Unsold
Securities
to be
Carried
Forward
 
Newly Registered Securities
                         
Fees to Be
Paid
  Equity   Common stock, $0.0001 per share   457(r)   6,555,000
(2)
  $44.00   $288,420,000.00   0.00015310   $44,157.11
  —    —    —   
                         
Fees to Be
Paid
  Equity  
Pre-funded
warrants to purchase common stock
  457(r)   655,500   $44.00
(3)
 
(3)
  0.00015310  
(3)
         
                         
Fees
Previously
Paid
      —                     
 
Carry Forward Securities
                         
Carry
Forward
Securities
      —              —    —    —   
                   
    Total Offering Amounts     $288,420,000.00     $44,157.11          
                   
    Total Fees Previously Paid                  
                   
    Total Fee Offsets                  
                   
    Net Fee Due               $44,157.11                

(1)
Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended (the “Securities Act”). The fee payable in connection with the offering pursuant to this prospectus supplement has been paid in accordance with Rule 456(b) under the Securities Act, and represents deferred payment of the registration fees in connection with the registrant’s Registration Statement on
Form S-3ASR
(File
No. 333-282912).
 
(2)
Includes 855,000 shares of common stock that the underwriters have an option to purchase and 655,500 shares of common stock that are issuable upon the exercise of the
pre-funded
warrants referenced below.
 
(3)
Represents the sum of the offering price of $43.9999 per
pre-funded
warrant and the exercise price of $0.0001 per share issuable pursuant to the
pre-funded
warrants. Pursuant to Securities and Exchange Commission staff interpretation, the entire fee is allocated to the common stock underlying the
pre-funded
warrants.